$11.56. Raidy previously served as a Board Member or Board Observer of Semma Therapeutics, Repare Therapeutics, Pliant Therapeutics, Oncorus and Orchard Therapeutics. Pliant Therapeutics to Present Data at The Liver Meeting® 2020 Novartis Institutes for Biomedical Research and Agent Capital are the most recent investors. Blazing a new path in medicine. Pliant Therapeutics, Inc. (PLRX), a clinical stage biotechnology company focused on discovering and developing novel thera. Homepage - Scorpion Therapeutics Novartis Leads $100M Round for Fibrosis-Focused Pliant ... Pliant Therapeutics executives and stock owners. SEC Filing - Pliant Therapeutics, Inc. Charles S. Kim. The funding round was led by Novartis, with Redmile Group, Farallon Capital Management, Surveyor Capital (a Citadel company . Salaries posted anonymously by Pliant Therapeutics employees. San Francisco, CA 94111 (415) 693-2000 Pliant Therapeutics, Inc. Common Stock (PLRX) Stock Price ... Pliant is a clinical-stage biopharmaceutical company, with two lead assets namely PLN-74809 . Pliant Therapeutics, Inc. 260 Littlefield Avenue. San Francisco, CA 94111 (415) 693-2000 Call. All other trademarks or trade names referred to in this prospectus or in the documents incorporated by reference into this prospectus are the property of their respective owners. . PROSPECTUS . Job Title. About Pliant Therapeutics Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases. Pliant Therapeutics - Staking Claim In Tackling Fibrotic ... SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40 th Annual J.P . Pliant Therapeutics, Inc. Common Stock (PLRX) Nasdaq Listed. It is focused on discovering and developing novel therapies for the treatment of fibrosis. on November 30, 2020. When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. Ramius Advisors | Leading with Vision | Capabilities - Cowen Learn More → 02-28-2022. Closed opens 9:00am. Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a poster . Hoyoung Huh Net Worth (2022) | wallmine GB 101 California Street 5th Floor. CAMBRIDGE, Mass., March 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult subjects. South San Francisco, California 94080. What does Pliant Therapeutics's logo look like? Storefront. +0.41 (+3.68%) DATA AS OF Feb 15, 2022. A free inside look at Pliant Therapeutics salary trends based on 10 salaries wages for 9 jobs at Pliant Therapeutics. In-store purchases only. Pliant Therapeutics, Inc. 260 Littlefield Avenue. (RTTNews) - The lockup period of Pliant Therapeutics Inc. (PLRX) ends today, i.e. Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. . Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California. Learn More . Pliant Therapeutics is a clinical stage biopharmaceutical company developing novel therapies for the treatment of fibrosis diseases. The price trend for Pliant Therapeutics, Inc. (PLRX) has been bearish lately and the stock has lost 5.7% over the past four weeks. $30 / hr. Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases. Pliant Therapeutics Inc. company facts, information and financial ratios from MarketWatch. About Pliant Therapeutics Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases. South San Francisco, CA 94080 (650) 481-6770 : Kristin VanderPas. Pliant Therapeutics has a post-money valuation in the range of $500M to $1B as of Mar 4, 2020, according to PrivCo. Pliant Therapeutics Snares $100M Crossover Round March 03, 2020 Targeting scar tissue that builds up and blocks the lungs and bile ducts, Pliant Therapeutics Inc. raised a $100 million round from giant Novartis AG and a band of crossover investors that will launch its marquee drug through mid-phase clinical trials and set up the South San . USA-based clinical-stage biotech Pliant Therapeutics today announced that it has raised $100 million in a Series C financing. Sean Clayton. Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results. Prior to his role at Cowen Healthcare Investments, Mr. Raidy was Cowen's Head of Investment Banking and prior to that he served as co-head of Cowen's equity capital markets group . Eikon Therapeutics, a pioneer in the application of live-cell super-resolution microscopy to drug discovery, announced that it has closed a $517.8 million Series B financing. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. Phone 1 650 481-6770. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening . Sign up for a free trial to view exact valuation and search companies with similar valuations. The Swiss pharmaceutical giant made good on that . By leveraging its powerful product engine, Pliant's mission is to prevent or even reverse fibrosis, restoring organ function. KARTOS THERAPEUTICS is a clinical stage biopharmaceutical company with an investigational MDM2 inhibitor, navtemadlin (KRT-232) 275 Shoreline Drive, Suite 300 Redwood City, CA 94065 +1 650.542.0130 info@kartosthera.com Novartis Institutes for Biomedical Research and Agent Capital are the most recent investors. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illnesses. 3 Disclosed Funding Rounds $207,445,146. South San Francisco, CA 94080 (650) 481-6770 : Kristin VanderPas. See your local laws & regulations for more details. A valid medical marijuana authorization and government-issued ID are required to purchase cannabis products sold at medical retailers. The Company's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of αvβ6 and αvβ1 integrins that is in clinical development for the treatment of . 101 California Street 5th Floor. Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2021 financial results. Pliant Therapeutics Inc. 260 Littlefield Avenue. The company s lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. . 0 Participating Investments Pharmaceutical, Therapeutics, Health Care, Recruiting, Biotechnology, Health Diagnostics. Directions. Pliant Therapeutics Q4 EPS $(0.68) Down From $(0.54) YoY, Sales $2.00M Down From $4.46M YoY Targeted protein degradation is only the beginning. Add to Portfolio. This compares to loss of $0.54 per share a year ago. Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. $25. About Pliant Therapeutics Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases. Moody's Daily Credit Risk Score Risk $75,390 / yr. Of the 29 institutional investors that sold Pliant Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Eventide Asset Management LLC ($2.14M), Logos Global Management LP ($0.32M), Redmile Group LLC ($0.23M), BlackRock Inc. ($0.12M), Bank of New York Mellon Corp ($0.12M), Millennium Management LLC ($46.05K), and Citadel . Pliant Therapeutics executives and other stock owners filed with the SEC include: Units . $5. Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. Fiscal Year-end 12/2021 . Directions. Aligos is focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis . Pliant Therapeutics, Inc. 260 Littlefield Avenue . Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. This is the Pliant company profile. Senior Research Associate salaries - 1 salaries reported. The company's lead product . Partner Content. SOUTH SAN FRANCISCO, Calif., March 3, 2020 /PRNewswire/ — Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that it has raised $100 million in a Series C . Data is currently not available. THIS AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT (this "Agreement"), is made as of the 19th day of December, 2019, by and among PLIANT THERAPEUTICS, INC., a Delaware corporation (the "Company"), and each of the investors listed on Schedule A hereto, (together with any subsequent investors who become parties hereto as . SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat as . Directions. Sign up for a free trial to view exact valuation and search companies with similar valuations. Storefront. Pliant Therapeutics, Inc. (PLRX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.76. It was on this day, last year, i.e., June 3, 2020, that the . David Peinsipp. Pliant Therapeutics executives and stock owners. Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers. Pliant Therapeutics, Inc. Common Stock . Sector Health Care/Life Sciences. Pliant Therapeutics is funded by 14 investors. Pliant Therapeutics Inc. SEC filings breakout by MarketWatch. Benefits information above is provided anonymously by current and former Pliant Therapeutics employees, and may include a summary provided by the employer. Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases March 3, 2020. Learn about Pliant Therapeutics , including insurance benefits, retirement benefits, and vacation policy. See your local laws & regulations for more details. What does Pliant Therapeutics's logo look like? Of the 29 institutional investors that sold Pliant Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Eventide Asset Management LLC ($2.14M), Logos Global Management LP ($0.32M), Redmile Group LLC ($0.23M), BlackRock Inc. ($0.12M), Bank of New York Mellon Corp ($0.12M), Millennium Management LLC ($46.05K), and Citadel . A valid medical marijuana authorization and government-issued ID are required to purchase cannabis products sold at medical retailers. The company's lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. Glassdoor is your resource for information about Pliant Therapeutics benefits and perks. Salary. David Peinsipp. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. $141,348 / yr. Research Associate I salaries - 1 salaries reported. Pliant Therapeutics, Inc. (PLRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. However, the formation of a hammer chart pattern in its last . Fremont, CA: Pliant Therapeutics, a clinical-stage biopharmaceutical company focused on developing and discovering novel therapies for the treatment of fibrosis, raised $100 million in Series C round of financing. Pliant Therapeutics is an early-stage biotechnology company harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases. Directions. $50. Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. In addition to this technical chart pattern, strong . While Pliant Therapeutics shareholders are down 65% for the year, the market itself is up 4.5%. View the PLRX U.S. Securities and Exchange Commission reporting information. SOUTH SAN FRANCISCO, Calif., March 3, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced that it has raised $100 million in a Series C financing. Glassdoor gives you an inside look at what it's like to work at Pliant Therapeutics, including salaries, reviews, office photos, and more. Nurix Therapeutics | 5,999 followers on LinkedIn. It is focused on discovering and developing novel therapies for the treatment of fibrosis. PLRX: Pliant Therapeutics balance sheet. South San Francisco, CA 94080 (650) 481-6770 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT . Visit Site. "In 2021 strong execution drove significant advancement of our pipeline. Pliant Therapeutics. About Pliant Therapeutics Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel targeted therapies to slow or halt the progression of multiple life-threatening fibrotic diseases. Pliant Therapeutics executives and other stock owners filed with the SEC include: Pliant Therapeutics is funded by 14 investors. Pliant Therapeutics, Inc. . The company's lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. The company's lead . The company's lead product . Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share. These costs for the three months ended December 31, 2021, were $6.1 million, compared to $5.2 million in the three months ended December 31, 2020. Warrants . Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California. Industry Biotechnology. Ramius is a focused and fundamentally research-driven merger arbitrage strategy. Nasdaq 100. Scientist II salaries - 2 salaries reported. Pliant Therapeutics, Inc. Common Stock (PLRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Pliant plans to use the proceeds from the financing to support the continued clinical development of PLN-74809 in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as well as its ongoing drug discovery programs targeting other fibrotic diseases. Pliant plans to use the proceeds from the financing to support the continued clinical development of PLN . This is the Pliant Therapeutics company profile. PrimeC is a novel extended-release oral . | Nurix Therapeutics discovers drugs that harness the body's . Cooley LLP. Debt Securities . Pliant Therapeutics Salaries. The company's lead product candidate, PLN-74809, is currently in Phase 2 testing for IPF. Sean Clayton. Enter Symbol. General and administrative expenses for the year . Preferred Stock . Call. The current Ramius merger arbitrage team has managed merger arbitrage strategies since 2011. Most recently John exercised 17,500 units of PLRX stock worth $195,300 on 31 August 2018. About Us. Closed opens 9:00am. , you can buy Pliant Therapeutics Inc stock in any dollar amount, or any other fund or stock you know on Stash. The company also aims to build a patient registry for certain areas . Starboard Value is a New York-based investment adviser with a focused and fundamental approach to investing in publicly-traded US companies. Get the latest balance sheet from Zacks Investment Research. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California. Add to Watchlist. Pliant Therapeutics: $0 - $4,999: Dean Sheppard: University of California, San Francisco: Conflict of Interest: Pliant Therapeutics: $0 - $4,999: Other search results for: "Dean Sheppard" . From time to time, we may offer and sell our common stock, preferred stock, debt securities, warrants and/or units consisting of some or all of these securities, in any combination, together or separately, in one or more offerings, in amounts, at prices and on terms that will be . Pliant Therapeutics executives and stock owners. At Scorpion Therapeutics, we aim to transform cancer care and thereby improve the lives and survival rates of patients with cancer through optimized precision oncology. Aligos Therapeutics, Inc. is a privately held biotechnology company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases. It is focused on discovering and developing novel therapies for the treatment of fibrosis. Glassdoor gives you an inside look at what it's like to work at Pliant, including salaries, reviews, office photos, and more. 870-709-0800. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve . All content is posted anonymously by employees working at Pliant. Charles S. Kim. Pliant Therapeutics has a post-money valuation in the range of $500M to $1B as of Mar 4, 2020, according to PrivCo. Pliant Therapeutics is a clinical stage biopharmaceutical company unraveling and targeting the key biological pathways driving fibrosis. Cooley LLP. John has made over 17 trades of the Pliant Therapeutics stock since 2014, according to the Form 4 filled with the SEC. 870-709-0800. We use various trademarks and trade names in our business, including without limitation our corporate name and logo. Our team comprises an experienced group of recognized leaders in their respective fields, looking to lead a new era of precision oncology by filling the gaps in . Pliant Therapeutics executives and other stock owners filed with the SEC include: All content is posted anonymously by employees working at Pliant Therapeutics. What does Pliant Therapeutics's logo look like? In-store purchases only.